Aligos Therapeutics (ALGS) Competitors $10.44 +0.45 (+4.50%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$10.20 -0.24 (-2.35%) As of 10/20/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALGS vs. CRBU, TRDA, FHTX, PYXS, CLLS, EPRX, VOR, GNFT, CABA, and ACRSShould you be buying Aligos Therapeutics stock or one of its competitors? The main competitors of Aligos Therapeutics include Caribou Biosciences (CRBU), Entrada Therapeutics (TRDA), Foghorn Therapeutics (FHTX), Pyxis Oncology (PYXS), Cellectis (CLLS), Eupraxia Pharmaceuticals (EPRX), Vor Biopharma (VOR), GENFIT (GNFT), Cabaletta Bio (CABA), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry. Aligos Therapeutics vs. Its Competitors Caribou Biosciences Entrada Therapeutics Foghorn Therapeutics Pyxis Oncology Cellectis Eupraxia Pharmaceuticals Vor Biopharma GENFIT Cabaletta Bio Aclaris Therapeutics Aligos Therapeutics (NASDAQ:ALGS) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership. Do analysts recommend ALGS or CRBU? Aligos Therapeutics presently has a consensus price target of $50.00, suggesting a potential upside of 378.93%. Caribou Biosciences has a consensus price target of $6.67, suggesting a potential upside of 136.41%. Given Aligos Therapeutics' higher possible upside, equities analysts plainly believe Aligos Therapeutics is more favorable than Caribou Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aligos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Caribou Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more risk & volatility, ALGS or CRBU? Aligos Therapeutics has a beta of 2.77, suggesting that its stock price is 177% more volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.59, suggesting that its stock price is 159% more volatile than the S&P 500. Is ALGS or CRBU more profitable? Caribou Biosciences has a net margin of -1,800.93% compared to Aligos Therapeutics' net margin of -2,337.24%. Aligos Therapeutics' return on equity of -22.41% beat Caribou Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Aligos Therapeutics-2,337.24% -22.41% -12.09% Caribou Biosciences -1,800.93%-62.35%-49.65% Does the media refer more to ALGS or CRBU? In the previous week, Aligos Therapeutics had 2 more articles in the media than Caribou Biosciences. MarketBeat recorded 4 mentions for Aligos Therapeutics and 2 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 1.17 beat Aligos Therapeutics' score of 0.24 indicating that Caribou Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aligos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Caribou Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation and earnings, ALGS or CRBU? Aligos Therapeutics has higher earnings, but lower revenue than Caribou Biosciences. Caribou Biosciences is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAligos Therapeutics$3.94M16.30-$131.21M-$19.79-0.53Caribou Biosciences$9.12M28.79-$149.10M-$1.78-1.58 Do institutionals and insiders hold more shares of ALGS or CRBU? 60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 4.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 8.3% of Caribou Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryCaribou Biosciences beats Aligos Therapeutics on 9 of the 16 factors compared between the two stocks. Get Aligos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALGS vs. The Competition Export to ExcelMetricAligos TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.45M$3.46B$6.15B$10.56BDividend YieldN/A2.27%5.72%4.84%P/E Ratio-0.5323.3929.4727.34Price / Sales16.30483.15585.88238.70Price / CashN/A45.2825.8230.35Price / Book-1.3910.6112.526.69Net Income-$131.21M-$52.56M$3.32B$276.46M7 Day Performance8.07%3.95%1.80%-0.08%1 Month Performance7.96%16.10%8.79%3.93%1 Year Performance43.21%15.08%64.28%33.89% Aligos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALGSAligos Therapeutics3.8946 of 5 stars$10.44+4.5%$50.00+378.9%+44.0%$61.45M$3.94M-0.5390CRBUCaribou Biosciences2.5545 of 5 stars$2.38-4.4%$6.67+180.1%+41.0%$231.88M$9.99M-1.34100Gap DownTRDAEntrada Therapeutics2.906 of 5 stars$5.81-4.6%$25.67+341.8%-64.2%$231.65M$210.78M-3.26110FHTXFoghorn Therapeutics2.5858 of 5 stars$4.29+5.7%$11.00+156.4%-47.3%$229.51M$22.60M-3.61120PYXSPyxis Oncology2.8625 of 5 stars$3.45-6.8%$7.75+124.6%-4.5%$229.47M$16.15M-2.1660CLLSCellectis2.1887 of 5 stars$4.42+9.4%$4.00-9.5%+107.9%$224.56M$49.22M-5.39290Analyst ForecastGap UpEPRXEupraxia Pharmaceuticals2.631 of 5 stars$6.05-0.3%$11.00+81.8%+134.3%$218.28MN/A-7.1229Short Interest ↑VORVor Biopharma2.8819 of 5 stars$32.29+3.4%$113.83+252.5%N/A$214.05MN/A-0.12140Insider TradeGap UpGNFTGENFIT1.9534 of 5 stars$4.25flat$7.00+64.7%-31.3%$212.52M$76.77M0.00120Positive NewsCABACabaletta Bio2.7378 of 5 stars$2.49+7.3%$13.44+439.9%-42.5%$212.20MN/A-0.9250Gap UpACRSAclaris Therapeutics2.7468 of 5 stars$1.91+2.1%$8.71+356.2%+68.9%$202.58M$18.72M-1.39100Positive NewsAnalyst ForecastAnalyst RevisionGap Up Related Companies and Tools Related Companies Caribou Biosciences Competitors Entrada Therapeutics Competitors Foghorn Therapeutics Competitors Pyxis Oncology Competitors Cellectis Competitors Eupraxia Pharmaceuticals Competitors Vor Biopharma Competitors GENFIT Competitors Cabaletta Bio Competitors Aclaris Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALGS) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
